Dr. Dugar founded Sphaera Pharma in 2008 to establish a new and unique model for capital efficient drug discovery and development that has successfully formed more than a dozen collaborative relationships with investigators at research organizations and biotech companies in the US and Singapore. These have led to multiple platform technologies, spin-offs, and licensing deals, including Sphaera-generated IP responsible for the founding of Cardero Therapeutics, where Dr. Dugar also serves as COO. Dr. Dugar's model integrates scientific and business skills to advance new medicines benefitting patients, providers, and investors.
Dr. Dugar has more than 30 years of drug discovery and development experience including tenures at Bristol Myers Squibb and Schering-Plough. He was founder of Advantium Pharma, a full-service India-based CRO that was sold to Sequoia Capital, and Vice President at Johnson & Johnson/Scios Inc, a company formed by J&J's acquisition of Scios where he helped build the small molecule drug discovery program. He is a co-inventor of Zetia® and Vytorin® and was a recipient of the National Inventor of the Year Award in 2005, American Chemical Society's
Heroes of Chemistry Award in 2004, New Jersey R&D Council's Thomas Alva Edison Patent Award in 2002. He has co-authored over 60 publications and presentations and co-invented over 100 issued and applied patents.
Dr. Dugar earned his PhD from University of California at Davis and held post-doctoral fellowships at Swiss Federal Institute of Technology (ETH) Zurich and Cornell University, NY.